Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
62
resultados
Última actualización
17/03/2025 [07:24:00]
Resultados 25 a 50 de 62
Resumen de: WO2023198960A1
The present disclosure relates to a method for determining a risk of development or risk of presence of Alzheimer's disease in a human subject comprising analyzing an activity of a PIEZO1 receptor. The disclosure also relates to a kit for determining a risk of development or risk of presence of Alzheimer's disease according to the present method. The disclosure also relates to an in vitro use of a PIEZO1 receptor as a biomarker and and determination of intracellular calcium level as a biomarker for determining a risk of development or risk of presence of Alzheimer's disease in a human subject.
Resumen de: US2025051429A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: US2025049741A1
The present invention relates to a composition for preventing or treating Alzheimer's disease, comprising a phospholipase C (PLC) activator as an active ingredient. A composition comprising the PLC activator of the present invention as an active ingredient restores the S-eCB mobilization suppressed by AβO, recovers the synaptic plasticity impaired by AβO, and not only recovers PLCβ1 protein levels to normal levels in AβO-treated mouse hippocampal slices and 5XFAD mouse hippocampal slices in the chronic stage of AD, but also recovers contextual fear memory impairment in AD mice, and thus is expected to be usefully used for preventing or treating Alzheimer's disease.
Resumen de: US2025052675A1
Provided herein is a biosensor for conformation and secondary structure analysis, notably for the direct non-invasive qualitative secondary structure analysis of a single selected protein within a complex mixture, as e.g. a body fluid, by vibrational spectroscopic methods. For the analysis it is not required that the selected substance be isolated, concentrated, or pretreated by a special preparative procedure.
Resumen de: US2025049883A1
Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAX™ for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAX™ effectively improved the sensory function in patients with diabetic neuropathy.
Resumen de: WO2025030768A1
A combined detection kit for detecting sepsis and the use thereof. The present invention relates to the use of a combination of at least two markers of CD14, CD95, HBP, HMGB-1, IFN-α, IFN-γ, IL-1β, IL-8, MIP-1β, MIF, PCT, TNF-α, sTREM-1, TLR-4 and TSP-1 in the detection of sepsis. The early diagnosis and screening of sepsis can be achieved by means of detecting relevant samples such as blood, urine, cerebrospinal fluid, feces, sputum or tissue fluid and combining algorithms to build a model, and bacterial infection, viral infection and sepsis can be distinguished. The combined detection kit has good diagnosis results in both the systemic inflammatory response stage and the compensatory anti-inflammatory response stage of sepsis; and under the condition of 98% specificity, the diagnosis sensitivity can reach 98%.
Resumen de: WO2025030769A1
The present invention relates to the technical field of biological medicines. Disclosed are a combined detection kit for assisting in diagnosis of Alzheimer's disease and the use. Disclosed is the combined use of at least four of amyloid β-proteins, phosphorylated Tau proteins, biomarkers of neurodegeneration or neuron damage, and biomarkers related to neuroimmune disorder, synaptic dysfunction and blood brain barrier alternation in assisting in diagnosis of Alzheimer's disease. Compared with single-biomarker detection existing in the market and the combined detection using a small number of markers disclosed in some published patents, the marker combined detection provided by the present invention achieves a higher specificity or sensitivity. The present invention establishes a brand-new algorithm model, and both AD scale rating and brain function imaging diagnosis result rating are incorporated into the algorithm model for cooperative diagnosis; under the condition of a 95% specificity, the diagnosis sensitivity thereof can reach 95%, which is far higher than that of similar products in the market.
Resumen de: WO2025032070A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: WO2025032091A1
The present invention relates to a splice variant of a CERT1 protein that acts as a biomarker for a TDP-43 pathology, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), but also other neurological diseases, such as Alzheimer's disease. In particular, the present invention relates to methods for identifying a splice variant of CERT1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject and to methods for predicting whether a therapy is likely to be successful. Also claimed are antibodies binding to the CERT1 splice variant and kits comprising the antibody.
Resumen de: WO2025031900A1
The present invention relates to a human ectoderm derived brain cell characterized by the following features: (1) the intron between exons 10 and 11 of the MAPT gene encoding the Tau protein has been removed by genome-editing from one or both allele(s); and (2) at least one of the alleles of the MAPT gene of (1) carries at least one mutation enhancing Tau aggregation and at least one mutation enhancing nucleation of Tau aggregation; or (3) one allele of the MAPT gene as defined in claim 1(1) carries at least one mutation enhancing Tau aggregation, preferably in exon 10, and the other allele carries at least one mutation enhancing nucleation of Tau aggregation, preferably in exon 11.
Resumen de: US2025051428A1
The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies.
Resumen de: WO2023196927A1
The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and/or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.
Resumen de: AU2023207441A1
The invention relates to an
Resumen de: AU2023329330A1
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Resumen de: AU2025200383A1
Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAXT for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAXTM effectively improved the sensory function in patients with diabetic neuropathy.
Resumen de: US2025042979A1
Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.
Resumen de: US2025043349A1
Scents are perceived by the olfactory sensory neurons (OSNs) that line the upper nasal cavity. Each OSN expresses one odorant receptor, and these odorant receptors contact the scent molecules. Methods for determining which odorant receptor(s) are activated by a scent are lacking, making it difficult to replicate or improve scents. The technology as disclosed herein refers to methods relating to activating odor response genes found in olfactory sensory neurons after the neurons are exposed to at least one volatilized chemical compound.
Resumen de: CA3242558A1
Aspects of the application relate to methods and systems for obtaining information regarding multiple amino acids in a polypeptide based on binding interactions between the polypeptide and one or more amino acid recognizers. Kinetic signature information may be obtained from a series of signal pulses indicative of a series of binding events between one or more amino acid recognizers and an amino acid of a polypeptide (e.g., a terminal amino acid, an internal amino acid). The kinetic signature information (e.g., pulse duration, interpulse duration, recognition segment (RS) duration, intersegment duration) may be used to determine one or more chemical characteristics (e.g., identity, modification) of multiple amino acids of the polypeptide.
Resumen de: AU2023294616A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Resumen de: US2025032580A1
Uses of ADNF polypeptides in therapy are provided. Accordingly, there is provided a method of treating a disease associated with visual evoked potential impairment and/or speech impairment that is not due to vocal disturbance and in which the subject suffers from the visual evoked potential impairment and/or speech impairment, the method comprising administering to the subject a therapeutically effective amount of an ADNF polypeptide, wherein said ADNF polypeptide has a neurotrophic/neuroprotective activity in an in vitro cortical neuron culture assay.
Resumen de: WO2025024817A1
Embodiments of the instant disclosure relate to diagnosis and/or early diagnosis, intervention and/or treatment of Alzheimer's disease (AD). Certain embodiments relate to methods for identifying and isolating/analyzing an enriched population of neuronal, microglial and/or astrocytic exosomes from a sample of a subject and detecting biomarkers of interest on one or more exosomes in the enriched population to diagnose a neurodegenerative condition, Alzheimer's disease (AD), an AD-related dementia/condition, Down Syndrome (DS) or the like at an earlier stage than afforded by current therapies using minimally invasive technologies at reduced costs in time and expenses. Other embodiments relate to assessing interventions and evaluating treatment regimens for neurodegenerative disorders using approaches disclosed herein.
Resumen de: US2025032501A1
The present technology relates to methods for treating, preventing, and/or ameliorating Alzheimer's disease, in a subject in need thereof. In particular aspects, the present technology relates to the use of MAPK inhibitors to treat, prevent, and/or ameliorate Alzheimer's disease.
Resumen de: US2025032444A1
The present invention is directed to 4-methylumbelliferone (hymecromone) or a derivative thereof for use in the treatment of major depressive disorder, mood disorders, anxiety-related disorders and depression associated with diseases or drug treatments including Alzheimer's disease, HIV associated neurocognitive disorders (HAND), psoriasis, chronic fatigue syndrome, Parkinson's disease, Long COVID syndrome and drug treatment regimens with IFN-alpha or vitamin A analogues, promoted by pathogenic extracellular vesicles, wherein 4-methylumbelliferone inhibits hyaluronic acid (HA) synthases and block the incorporation of HA and/or low molecular weight cleavage products into said extracellular vesicles. The present invention is also directed to a method for monitoring the efficacy of the treatment and delivery of therapeutic cargo to cells incorporating pEV by means of HA-binding receptors. The present invention further provides an in vitro screening method for identifying further inhibitors of HA synthases.
Resumen de: EP4498086A2
An embodiment according to the present invention provides a kit or device for detection of dementia, and a method for detecting dementia. An embodiment according to the present invention relates to: a kit or device for detection of dementia, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting dementia, including measuring the miRNA(s) in vitro.
Nº publicación: CL2024002309A1 24/01/2025
Solicitante:
EISAI R&D MAN CO LTD [JP]
EISAI R&D MANAGEMENT CO., LTD
Resumen de: MX2024009492A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
BOPI
Sede Electrónica
